Ongentys

(Opicapone)

Ongentys

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 25 mg, 50 mg)
Drug ClassCatechol-O-methyltransferase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.